Overview

QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors

Status:
Withdrawn
Trial end date:
2019-08-23
Target enrollment:
Participant gender:
Summary
This is a phase 2 study of AMG 337 in subjects with advanced or metastatic solid tumors that overexpress MET or harbor METex14del mutations resulting in MET exon 14 skipping.
Phase:
Phase 2
Details
Lead Sponsor:
NantPharma, LLC